Literature DB >> 24402193

Circadian variation in the effect of intravenous thrombolysis after non-lacunar stroke.

Manuel Cappellari1, Paolo Bovi, Giuseppe Moretto.   

Abstract

The onset of non-lacunar stroke symptoms has a circadian variation, with a higher risk in the early morning hours and lower risk during the nighttime period, but this circadian distribution has not been clearly established on the effect of intravenous (IV) thrombolysis. The aim of the present study was to assess whether the time interval based on time of Alteplase IV infusion may influence the effect of treatment in patients with non-lacunar stroke. We conducted an analysis on prospectively collected data of 476 non-lacunar stroke patients treated with IV thrombolysis. To identify a possible circadian variation in the effect of Alteplase IV infusion, we used the following outcome measures: major neurological improvement (NIH stroke scale [NIHSS] score decrease of ≤8 points from baseline or NIHSS score of 0 at 24 h), and hemorrhagic transformation according to European Cooperative Acute Stroke Study trial definition within 24 h. Multivariate analysis showed that ORs for major neurological improvement were lower in patients who started IV thrombolysis in the 6 AM-noon interval (OR 0.35, 95% CI 0.16-0.74, p = 0.006) and noon-6 PM interval (OR 0.40, 95% CI 0.20-0.81, p = 0.010), whereas ORs for hemorrhagic transformation were lower in patients who started IV thrombolysis in the noon-6 PM interval (OR 0.29, 95% CI 0.12-0.67, p = 0.004) and in the 6 PM-midnight interval (OR 0.26, 95% CI 0.11-0.62, p = 0.002), compared with midnight-6 AM interval. The effect of Alteplase IV infusion could show a circadian variation in patients with non-lacunar stroke. After comparison with the midnight-6 AM interval, thrombolysis could be more safe from noon to midnight, and less effective from 6 AM to 6 PM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402193     DOI: 10.1007/s11239-013-1041-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

1.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

2.  Circadian variation in the timing of stroke onset: a meta-analysis.

Authors:  W J Elliott
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

3.  Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects.

Authors:  M B Turton; T Deegan
Journal:  Clin Chim Acta       Date:  1974-09-30       Impact factor: 3.786

4.  Circadian variation in ischemic stroke subtypes.

Authors:  S Chaturvedi; H P Adams; R F Woolson
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

7.  Benefit of thrombolysis for stroke is maintained around the clock: results from the SITS-EAST Registry.

Authors:  J Kõrv; R Vibo; P Kadlecová; A Kobayashi; A Czlonkowska; M Brozman; V Švigelj; L Csiba; K Fekete; V Demarin; A Vilionskis; D Jatuzis; Y Krespi; N Ahmed; R Mikulík
Journal:  Eur J Neurol       Date:  2013-09-16       Impact factor: 6.089

8.  Diurnal variation of the fibrinolytic system.

Authors:  V Grimaudo; J Hauert; F Bachmann; E K Kruithof
Journal:  Thromb Haemost       Date:  1988-06-16       Impact factor: 5.249

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  3 in total

Review 1.  New insight into ischemic stroke: Circadian rhythm in post-stroke angiogenesis.

Authors:  Yuxing Zhang; Lijuan Liu; Xin Zhao; Siyang Yan; Fukang Zeng; Desheng Zhou
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

Review 2.  Disruptions of Circadian Rhythms and Thrombolytic Therapy During Ischemic Stroke Intervention.

Authors:  Jennifer A Liu; James C Walton; A Courtney DeVries; Randy J Nelson
Journal:  Front Neurosci       Date:  2021-06-10       Impact factor: 4.677

Review 3.  Implications of Circadian Rhythm in Stroke Occurrence: Certainties and Possibilities.

Authors:  Dana Marieta Fodor; Monica Mihaela Marta; Lăcrămioara Perju-Dumbravă
Journal:  Brain Sci       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.